Abstract: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

Abstract: This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins.

Abstract: A catalytic process for the synthesis of aromatic primary amines, reagent compositions for effecting the process, and transition metal complexes useful in the process, are provided.

Abstract: A varicose vein dissector and removal apparatus includes a handle having a first end and a second end, a dissector extending from the first end of the handle and a hook extending from the second end of the handle, and a blade positioned within the dissector for movement between a use position and a storage position. The apparatus is used by creating an initial incision in skin over a varicose vein to be removed, advancing the dissector into the incision and dissecting around the varicose vein to be removed, pushing the dissector against an inner surface of the skin a predetermined distance from the initial incision, exposing the blade by moving it from its storage position to its use position and creating a second incision in the skin letting the dissector protrude out of the skin, and grasping the vein with the hook and removing the vein.

Abstract: Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed.

Abstract: One aspect of the present disclosure relates to a method or determining location(s) at which at least one magnetic article is to be positioned during a magnetic resonance imaging procedure of at least one subject. A magnetic field Bo is applied to a region that includes the at least one subject and does not include the at least one magnetic article. First magnetic resonance information about the region in response to the applied magnetic field BO is received. The first magnetic resonance information relates at least in part to one or more magnetic field inhomogeneities in the region. Based at least in part on the first magnetic resonance information, at least one first location proximate the at least one subject at which at least one paramagnetic article and/or diamagnetic article is to be positioned is determined, so as to at least partially compensate for the one or more magnetic field inhomogeneities.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.

Abstract: Methods are provided for evaluating an oocyte for fertilization and implantation. For example, methods are provided for determining whether an oocyte expresses, or does not express, one or more of a group of markers identified as differently expressed between chromosomally normal and chromosomally abnormal oocytes. Also provided, for example, are methods for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level.

Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.

Abstract: ?-peptide regions of polypeptides can serve as structural mimics of ?-helices in wild type proteins. Because ?-helices of one protein often bind to a target protein in a biological pathway, a polypeptide that contains a helical ?-peptide region can be used to disrupt this type of protein-protein binding. As a result, polypeptides that contain a helical ?-peptide region can be used to treat conditions involving this type of protein-protein binding, such as viral infections and cell proliferation.

Abstract: Separation processes using engineered osmosis are disclosed generally involving the extraction of solvent from a first solution to concentrate solute by using a second concentrated solution to draw the solvent from the first solution across a semi-permeable membrane. One or both of the solute and solvent may be a desired product. Enhanced efficiency may result from using low grade waste heat from industrial or commercial sources.

Abstract: An energy efficient desalination process that does not produce waste products involves the extraction of water from a first solution, such as seawater, by using a second concentrated solution to draw the water from the first solution across a semi-permeable membrane. By manipulating the equilibrium of the soluble and insoluble species of solute within the second solution in favor of the soluble species of the solute, a saturated second solution can be used to generate osmotic pressure on the first solution. Also, by adjusting the equilibrium in favor of the less soluble species after the water has been drawn from the first solution, a portion of the solute can easily be precipitated out. Heating the second solution decomposes the solute into its constituent gasses. The constituent gasses and precipitated solute may be recycled through the process to affect the changes in equilibrium and eliminate waste products.

Abstract: External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations may be administered via inhalation, injection, or orally. The formulations may be in the form of an ointment, lotion, cream, gel, drop, suppository, spray, liquid, powder, granule, solution, suspension, capsule, or tablet. Methods of treating inflammatory or related diseases by administering an effective amount of an EGS in a pharmaceutically acceptable carrier are also described.

Abstract: A dynamic spine stabilizer moves under the control of spinal motion providing increased mechanical support within a central zone corresponding substantially to the neutral zone of the injured spine. The dynamic spine stabilizer includes a support assembly and a resistance assembly associated with the support assembly. The resistance assembly generates greater increase in mechanical force during movement within the central zone and lesser increase in mechanical force during movement beyond the central zone. A method for using the stabilizer is also disclosed.

Abstract: Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor.

Abstract: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.

Abstract: The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety, of diagnostic, screening, and therapeutic methods.

Abstract: The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity.

Abstract: The present invention relates to the use of the compound according to formula (I) Where S is (A) or (B); X is H or F; R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (C) or (D) group; Where Nu is a radical of a biologically active compound such as an anticancer, antihyperproliferative or antiviral compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; Each R8 is independently H, or a C1-C20 alkyl or ether group, preferably H or a C1-C2 alkyl group; k is 0-12, preferably, 0-2; R2 is H, an acyl group or a C1-C20 alkyl or ether group; and pharmaceutically acceptable salts, solvates or polymorphs thereof for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states.